Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | Predicting resistance in CLL patients

Danielle Brander • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Venetoclax

Danielle Brander, MD, Duke University School of Medicine, Durham, NC, describes the process by which we aim to predict which patients will develop resistance to chronic lymphocytic leukemia (CLL) treatment, with particular reference to venetoclax treatment. This interview was recorded at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Danielle Brander

1:49
The management of Richter's transformation: current approaches and future outlooks
Danielle Brander • 8 Dec 2023
1:13
Exciting updates in CLL: advancing treatment for patients with double-refractory disease
Danielle Brander • 8 Dec 2023
1:46
Managing the side effects associated with BTKi treatment for CLL
Danielle Brander • 8 Dec 2023
2:06
Unmet need: CLL patients intolerant to novel therapies
Danielle Brander • 22 Sep 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals